Literature DB >> 12149358

Multicenter comparative evaluation of six commercial systems and the national committee for clinical laboratory standards m27-a broth microdilution method for fluconazole susceptibility testing of Candida species.

G Morace1, G Amato, F Bistoni, G Fadda, P Marone, M T Montagna, S Oliveri, L Polonelli, R Rigoli, I Mancuso, S La Face, L Masucci, L Romano, C Napoli, D Tatò, M G Buscema, C M C Belli, M M Piccirillo, S Conti, S Covan, F Fanti, C Cavanna, F D'Alò, L Pitzurra.   

Abstract

Fluconazole susceptibility among 800 clinical Candida isolates (60% C. albicans) and two control strains (C. krusei ATCC 6258 and C. parapsilosis ATCC 22019) was tested with the NCCLS M27-A method (gold standard) and six commercial products (Candifast, disk, Etest, Fungitest, Integral System Yeasts, and Sensititre YeastOne). Results were classified as susceptible, susceptible-dose dependent, or resistant using M27-A breakpoints or, for Fungitest, Integral System Yeasts, and Candifast, as susceptible, intermediate, or resistant, according to the manufacturers' instructions. Concordance with NCCLS M27-A results was analyzed with the chi(2) test. Intra- and interlaboratory reproducibility was also evaluated. NCCLS M27-A (90.1%), Etest (93.1%), Sensititre YeastOne (93.1%), disk (96.7%), Fungitest (92.6%), Integral System Yeasts (40.6%), and Candifast (6.0%) classified the indicated percentages of C. albicans isolates as susceptible. Among non-C. albicans strains, the percentages of susceptible isolates were as follows: NCCLS M27-A, 74.0%; Etest, 83.8%; Sensititre YeastOne, 64.1%; disk, 60.6%; Fungitest, 76.6%; Integral System Yeasts, 28.3%; and Candifast, 27.4%. All methods except Candifast and Integral System Yeasts showed good agreement with NCCLS M27-A results for both C albicans and non-C. albicans isolates. Intralaboratory reproducibility was excellent for NCCLS M27-A, Etest, Sensititre YeastOne, disk, and Fungitest (88 to 91%). Similar results emerged from the interlaboratory reproducibility evaluation. Our findings indicate that some commercial methods can be useful for fluconazole susceptibility testing of clinical Candida isolates. Those characterized by a lack of medium standardization and/or objective interpretative criteria should be avoided. Particular caution is necessary when testing is being done for clinical and epidemiological purposes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12149358      PMCID: PMC120637          DOI: 10.1128/JCM.40.8.2953-2958.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Commercial systems for fluconazole susceptibility testing of yeasts: comparison with the broth microdilution method.

Authors:  B Posteraro; L Romano; M Sanguinetti; L Masucci; G Morace; G Fadda
Journal:  Diagn Microbiol Infect Dis       Date:  2000-09       Impact factor: 2.803

3.  Comparative evaluation of PASCO and national committee for clinical laboratory standards M27-A broth microdilution methods for antifungal drug susceptibility testing of yeasts.

Authors:  B A Arthington-Skaggs; M Motley; D W Warnock; C J Morrison
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

4.  Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.

Authors:  J H Rex; T J Walsh; J D Sobel; S G Filler; P G Pappas; W E Dismukes; J E Edwards
Journal:  Clin Infect Dis       Date:  2000-04-20       Impact factor: 9.079

5.  Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients.

Authors:  S Perea; J L López-Ribot; W R Kirkpatrick; R K McAtee; R A Santillán; M Martínez; D Calabrese; D Sanglard; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

6.  International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program.

Authors:  M A Pfaller; D J Diekema; R N Jones; H S Sader; A C Fluit; R J Hollis; S A Messer
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

7.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

Review 8.  Fluconazole in transplant recipients: options and limitations.

Authors:  J Strahilevitz; A M Sugar; D Engelhard
Journal:  Transpl Infect Dis       Date:  2000-06       Impact factor: 2.228

9.  Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.

Authors:  D W Warnock; E M Johnson; T R Rogers
Journal:  J Antimicrob Chemother       Date:  1998-09       Impact factor: 5.790

10.  Comparison of a new commercial colorimetric microdilution method with a standard method for in-vitro susceptibility testing of Candida spp. and Cryptococcus neoformans.

Authors:  K G Davey; A Szekely; E M Johnson; D W Warnock
Journal:  J Antimicrob Chemother       Date:  1998-10       Impact factor: 5.790

View more
  20 in total

1.  Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole.

Authors:  M A Pfaller; D J Diekema; L Boyken; S A Messer; S Tendolkar; R J Hollis
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

2.  Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole.

Authors:  M A Pfaller; A Espinel-Ingroff; R N Jones
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

3.  Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp.

Authors:  M A Pfaller; D J Diekema; G W Procop; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2007-10-03       Impact factor: 5.948

4.  Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin.

Authors:  M A Pfaller; V Chaturvedi; D J Diekema; M A Ghannoum; N M Holliday; S B Killian; C C Knapp; S A Messer; A Miskov; R Ramani
Journal:  J Clin Microbiol       Date:  2008-05-07       Impact factor: 5.948

5.  Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp.

Authors:  M A Pfaller; D J Diekema; G W Procop; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2007-01-10       Impact factor: 5.948

6.  Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood.

Authors:  M J Maxwell; S A Messer; R J Hollis; L Boyken; S Tendolkar; D J Diekema; M A Pfaller
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

7.  Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study.

Authors:  A Espinel-Ingroff; F Barchiesi; M Cuenca-Estrella; A Fothergill; M A Pfaller; M Rinaldi; J L Rodriguez-Tudela; P E Verweij
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

8.  Comparison of two probes for testing susceptibilities of pathogenic yeasts to voriconazole, itraconazole, and caspofungin by flow cytometry.

Authors:  Cidália Pina-Vaz; Sofia Costa-de-Oliveira; Acácio G Rodrigues; Ana Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

9.  In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei.

Authors:  M Drago; M M Scaltrito; G Morace
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-16       Impact factor: 3.267

10.  Candidal colonization, strain diversity, and antifungal susceptibility among adult diabetic patients.

Authors:  Safia A Al-Attas; Soliman O Amro
Journal:  Ann Saudi Med       Date:  2010 Mar-Apr       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.